A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells

Molecular Medicine Reports

Volumn 8, Issue 1, 2013, Pages 195-200

  Choi, Eun Sun ^a   Han, Gyoonhee ^b   Park, Song Kyu ^c   Lee, Kiho ^c   Kim, Hyun Jung ^d   Cho, Sung Dae ^a   Kim, Hwan Mook ^e  

^a Chonbuk National University   (South Korea)

^b Yonsei University   (South Korea)

^c Korea University   (South Korea)

^d BioRunx Co Ltd   (South Korea)

^e Gachon University   (South Korea)

Author keywords

A248; Histone deacetylase inhibitor; Mcl 1; Prostate cancer; Specificity protein 1; Survivin

Indexed keywords

A 248; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; PROTEIN MCL 1; SURVIVIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROSTATIC NEOPLASMS; SP1 TRANSCRIPTION FACTOR;

EID: 84878933881     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1481     Document Type: Article

References (42)

1. Alshatwi AA, Hasan TN, Shafi G, Syed NA, Al-Assaf AH, Alamri MS and Al-Khalifa AS: Validation of the antiproliferative effects of organic extracts from the green husk of Juglans regia L. on PC3 human prostate cancer cells by assessment of apoptosis-related genes. Evid Based Complement Alternat Med 2012: Feb 6, 2012 (Epub ahead of print).
2. Malek A, Núñez LE, Magistri M, et al: Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7: e35130, 2012.
3. Soriano-Hernández AD, Galvan-Salazar HR, Montes-Galindo DA, et al: Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. Int Urol Nephrol 44: 471-477, 2012.
4. Sankpal UT, Abdelrahim M, Connelly SF, et al: Small molecule tolfenamic acid inhibits PC3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 72: 1648-1658, 2012.
5. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD and McCormick JJ: Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65: 1007-1017, 2005. (Pubitemid 40216463)
6. Chintharlapalli S, Papineni S, Ramaiah SK and Safe S: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67: 2816-2823, 2007. (Pubitemid 46548971)
7. Choi ES, Shim JH, Jung JY, et al: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 102: 742-748, 2011.
8. Shim JH, Shin JA, Jung JY, et al: Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev 20: 102-111, 2011.
9. Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG and Yun J: Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 7: e39870, 2012.
10. Roh MS, Kim CW, Park BS, et al: Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 9: 583-589, 2004. (Pubitemid 39158634)
11. Vallo S, Mani J, Stastny M, et al: The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs 31: 265-272, 2013.
12. Rikiishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011: May 18, 2011 (Epub ahead of print).
13. Perego P, Zuco V, Gatti L and Zunino F: Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol 83: 987-994, 2012.
14. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
15. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066, 2010.
16. Chou YW, Chaturvedi NK, Ouyang S, et al: Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett 311: 177-186, 2011.
17. Hudak L, Tezeeh P, Wedel S, et al: Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 72: 1719-1735, 2012.
18. Kim NH, Kim SN and Kim YK: Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochem Biophys Res Commun 404: 915-921, 2011.
19. Gravina GL, Marampon F, Giusti I, et al: Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol 40: 711-720, 2012.
20. Zhou X, Yang XY and Popescu NC: Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. Biochem Biophys Res Commun 420: 325-330, 2012.
21. Lai MT, Yang CC, Lin TY, Tsai FJ and Chen WC: Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urol Oncol 26: 182-189, 2008.
22. Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M and Kallioniemi OP: Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123: 2774-2781, 2008.
23. Abdelrahim M, Smith R 3rd, Burghardt R and Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64: 6740-6749, 2004. (Pubitemid 39297937)
24. Abdelrahim M, Samudio I, Smith R 3rd, Burghardt R and Safe S: Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277: 28815-28822, 2002.
25. Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448, 2005. (Pubitemid 41540621)
26. Yao JC, Wang L, Wei D, et al: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10: 4109-4117, 2004. (Pubitemid 38812490)
27. Wang L, Wei D, Huang S, et al: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003. (Pubitemid 38031822)
28. Zannetti A, Del Vecchio S, Carriero MV, et al: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 60: 1546-1551, 2000. (Pubitemid 30183423)
29. Hosoi Y, Watanabe T, Nakagawa K, et al: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 25: 461-468, 2004.
30. Ishibashi H, Nakagawa K, Onimaru M, et al: Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 60: 6531-6536, 2000.
31. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R 3rd, Li X and Safe S: Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68: 5345-5354, 2008.
32. Jutooru I, Chadalapaka G, Lei P and Safe S: Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285: 25332-25344, 2010.
33. Chu S and Ferro TJ: Sp1: regulation of gene expression by phosphorylation. Gene 348: 1-11, 2005. (Pubitemid 40410011)
34. Deniaud E, Baguet J, Chalard R, et al: Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition. PLoS One 4: e7035, 2009.
35. Choi KH, Shim JH, Huong LD, Cho NP and Cho SD: Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma. Oral Dis 17: 469-475, 2011.
36. Yu DC, Waby JS, Chirakkal H, Staton CA and Corfe BM: Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol Cancer 9: 276, 2010.
37. Xu J, Zhou JY, Wei WZ, Philipsen S and Wu GS: Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 68: 6718-6726, 2008.
38. Kadonaga JT, Courey AJ, Ladika J and Tjian R: Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 242: 1566-1570, 1988.
39. Pietrzak M and Puzianowska-Kuznicka M: p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol Chem 389: 383-393, 2008. (Pubitemid 351773909)
40. Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 344: 305-311, 1999. (Pubitemid 30011584)
41. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y and Yan B: The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 25: 3296-3306, 2006. (Pubitemid 43846314)
42. Wu J, Ling X, Pan D, et al: Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 280: 9745-9751, 2005. (Pubitemid 40409673)